11/01/2019 13:44:21

Endeavour Increases Its Ity Mine Ownership From 80% to 85%

  

ENDEAVOUR INCREASES ITS ITY MINE OWNERSHIP FROM 80% TO 85%

View News Release in PDF

Abidjan, January 11, 2019 - Endeavour Mining (TSX:EDV OTCQX: EDVMF) ("Endeavour") is pleased to announce that it has increased its ownership stake in the Ity mine from 80% to 85%.   

In exchange for the additional 5% interest in the Ity mine (relating to the Société des Mines d'Ity and Société des Mines de Daapleu entities), Endeavour granted DYD International Holding Limited, a company owned by Didier Drogba, 1,072,305 common shares amounting to a total consideration of approximately US$15 million (CAD$20 million) based on the signing reference share price of C$18.50. The transaction was signed on December 21, 2018 and closed yesterday evening.

Following this transaction, Endeavour owns 85% of the Ity mine, with the Government of Cote d'Ivoire owning 10% and SODEMI (a government-owned mining company) owning the remaining 5%.

CONTACT INFORMATION

Martino De Ciccio

VP - Strategy & Investor Relations

+44 203 011 2719

mdeciccio@endeavourmining.com

Brunswick Group LLP in London

Carole Cable, Partner

+44 7974 982 458

ccable@brunswickgroup.com

ABOUT ENDEAVOUR MINING CORPORATION

Endeavour Mining is a TSX listed intermediate African gold producer with a solid track record of operational excellence, project development and exploration in the highly prospective Birimian greenstone belt in West Africa. Endeavour is focused on offering both near-term and long-term growth opportunities with its project pipeline and its exploration strategy, while generating immediate cash flow from its operations.

Endeavour operates 4 mines across Côte d'Ivoire (Agbaou and Ity) and Burkina Faso (Houndé, Karma) which were expected to produce 555-590koz in 2018 at an AISC of $760-810/oz. For more information, please visit 

www.endeavourmining.com

Corporate Office: 5 Young St, Kensington, London W8 5EH, UK  

This news release contains "forward-looking statements" including but not limited to, statements with respect to Endeavour's plans and operating performance, the estimation of mineral reserves and resources, the timing and amount of estimated future production, costs of future production, future capital expenditures, and the success of exploration activities. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "expects", "expected", "budgeted", "forecasts", and "anticipates". Forward-looking statements, while based on management's best estimates and assumptions, are subject to risks and uncertainties that may cause actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the successful integration of acquisitions; risks related to international operations; risks related to general economic conditions and credit availability, actual results of current exploration activities, unanticipated reclamation expenses; changes in project parameters as plans continue to be refined; fluctuations in prices of metals including gold; fluctuations in foreign currency exchange rates, increases in market prices of mining consumables, possible variations in ore reserves, grade or recovery rates; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes, title disputes, claims and limitations on insurance coverage and other risks of the mining industry; delays in the completion of development or construction activities, changes in national and local government regulation of mining operations, tax rules and regulations, and political and economic developments in countries in which Endeavour operates. Although Endeavour has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Please refer to Endeavour's most recent Annual Information Form filed under its profile at www.sedar.com for further information respecting the risks affecting Endeavour and its business. AISC, all-in sustaining costs at the mine level, cash costs, operating EBITDA, all-in sustaining margin, free cash flow, net free cash flow, free cash flow per share, net debt, and adjusted earnings are non-GAAP financial performance measures with no standard meaning under IFRS, further discussed in the section Non-GAAP Measures in the most recently filed Management Discussion and Analysis.

Attachment

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
13 Jun
PNDORA
Hvad er det for noget eklatant ævl.Hvis man sammenholder de store fondes indtog på det danske aktiem..
24
13 Jun
PNDORA
Jeg er meget imponeret over Jyske bank og i særdeleshed analytikkeren Janne Vincent Kjær. Kunne rest..
20
12 Jun
PNDORA
er i dag ude med en dødsdoms artikel omkring Pandora. Artiklen er skrevet af en velanset analytiker,..
17
12 Jun
NOVO-B
Novo Nordisk aktien er d.d. steget med 120 kr. siden d. 25. nov. 2016. Dvs. fra 226 til 346 kr. 💪 ..
17
15 Jun
PNDORA
Udover den samme analyse blev offentligjort for snart 3 uger siden er det da glimrende at man igen, ..
16
10 Jun
VELO
https://clinicaltrials.gov/ct2/show/study/NCT03979365 Bliver også spændene, at se om Envarsus sna..
15
15 Jun
PNDORA
Mit take på Pandora: Tidligere ledelse ønskede at væksten for vækstens skyld. Det har vist sig, a..
14
13 Jun
PNDORA
Nå du mener som IKEA, KIA, Hyundai, Harald Nyborg, Jysk og alle de andre hvor ingen vil handle..;)Må..
13
13 Jun
 
Kildevand på flaske ligeledes. Forbyd det. Kildevand, der fragtes fra Frankrig og  Italien til Danma..
13
12 Jun
PNDORA
Uden at have noget kendskab til Per Hansen artiklen, så kan jeg med sikkerhed sige, at din kommentar..
13

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
2
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
3
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
4
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
5
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 10:49:59
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB2 - 2019-06-16 11:49:59 - 2019-06-16 10:49:59 - 1000 - Website: OKAY